ATE201990T1 - Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren - Google Patents

Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Info

Publication number
ATE201990T1
ATE201990T1 AT94909927T AT94909927T ATE201990T1 AT E201990 T1 ATE201990 T1 AT E201990T1 AT 94909927 T AT94909927 T AT 94909927T AT 94909927 T AT94909927 T AT 94909927T AT E201990 T1 ATE201990 T1 AT E201990T1
Authority
AT
Austria
Prior art keywords
inclusion complexes
pct
date
ranitidine
hxdrochloride
Prior art date
Application number
AT94909927T
Other languages
English (en)
Inventor
Wilfried Fischer
Karin Klokkers
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of ATE201990T1 publication Critical patent/ATE201990T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT94909927T 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren ATE201990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9306024 1993-03-05
PCT/EP1994/000645 WO1994020091A1 (en) 1993-03-05 1994-03-04 Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation

Publications (1)

Publication Number Publication Date
ATE201990T1 true ATE201990T1 (de) 2001-06-15

Family

ID=10984320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909927T ATE201990T1 (de) 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Country Status (10)

Country Link
US (1) US5665767A (de)
EP (1) EP0687174B1 (de)
JP (1) JPH09502698A (de)
AT (1) ATE201990T1 (de)
CA (1) CA2157190A1 (de)
CZ (1) CZ224995A3 (de)
DE (1) DE69427467T2 (de)
RU (1) RU2143896C1 (de)
WO (1) WO1994020091A1 (de)
ZA (1) ZA941544B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001129A1 (en) * 1994-07-06 1996-01-18 Farmarc Nederland B.V. Inclusion complexes of ranitidine
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
AU1513699A (en) * 1998-08-18 2000-03-14 Nikolai Borisovich Leonidov Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20040202694A1 (en) * 2003-04-11 2004-10-14 Vascular Control Systems, Inc. Embolic occlusion of uterine arteries
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
ATE502653T1 (de) * 2004-08-02 2011-04-15 Chiesi Farma Spa Verfahren zur herstellung einer piroxicam:beta- cyclodextrin-einschlussverbindung
RU2362785C2 (ru) * 2004-09-27 2009-07-27 Карджилл, Инкорпорейтед Комплексы с включением циклодекстрина и способы их получения
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
US8889243B2 (en) 2012-08-16 2014-11-18 3M Innovative Properties Company Mechanical fastening nets and methods of making the same
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity
EP4121116A4 (de) * 2020-03-19 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education Stabilisierung von verbindungen als cyclodextrinkomplexe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
DE69427467D1 (de) 2001-07-19
JPH09502698A (ja) 1997-03-18
US5665767A (en) 1997-09-09
ZA941544B (en) 1994-10-31
DE69427467T2 (de) 2002-06-06
RU2143896C1 (ru) 2000-01-10
WO1994020091A1 (en) 1994-09-15
EP0687174A1 (de) 1995-12-20
CZ224995A3 (en) 1995-12-13
CA2157190A1 (en) 1994-09-15
EP0687174B1 (de) 2001-06-13

Similar Documents

Publication Publication Date Title
DE69427467D1 (de) Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
DE69428334D1 (de) Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
DK1200418T3 (da) Nematodicide trifluorbutener
NO996053L (no) Parfymerte en- og to-fase blandinger for å redusere kroppslukt, samt fremgangsmåte ved anvendelse derav
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
BR9808396A (pt) Processo para aumentar a deposição de um agente benéfico de uma composição em barra, e, barra
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE229340T1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
DE69412760D1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
ATE273987T1 (de) Neue fucosylierte oligosaccharide und verfahren zu deren herstellung
DK0422497T3 (da) Inklusionskomplekser med Silybinin, deres fremstilling af farmaceutiske præparater, der indeholder dem
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
DK1140115T3 (da) Phospholipidkomplekser af proanthocyanidin A2 som antiatherosclerotiske midler
BR9408195A (pt) Conjugados de hirudina formados de uma hirudina e um ou vários compostos lipófilos e processo para a produção de conjugados de hirudina
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties